Background:

The breast cancer susceptibility gene (BRCA1) localizes to chromosome 17q. Mutations within this gene account for approximately 45% of families with high incidence of breast cancer and at least 80% of families with increased incidence of both early-onset breast cancer and ovarian cancer. A second breast cancer susceptibility gene, BRCA2, located on chromosome 13q12-13, also confers a high incidence of breast cancer, but unlike BRCA1, BRCA2 does not confer a substantially elevated risk of ovarian cancer. The BRCA2-Associated Factor 35 (BRAF35) protein forms a complex with BRCA2, which associates with condensed chromatin during histone H3 phosphorylation. BRAF35 expression levels are highest in proliferating tissues and parallel BRCA2 expression patterns. The structure of BRAF35 includes a kinesin-like coiled coil domain and a nonspecific DNA binding HMG domain. The chromatin localization of BRAF35 and antibody microinjection studies indicate a role for the BRAF35/BRCA2 complex in cell cycle regulation.

Alternative names:

HMG20B; BRAF35; HMGX2; HMGXB2; SMARCE1R; SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1-related; SMARCE1-related protein; BRCA2-associated factor 35; HMG box-containing protein 20B; HMG domain-

Clonality:

Polyclonal

Reactivity:

Human

Source:

Rabbit

Isotype:

Request info at info@sobekbio.com

Immunogen:

Synthesized peptide derived from the N-terminal region of human BRAF35. at AA rangle； 10-90

Concentration:

1mg/ml

Applications:

WB, IHC, IF, ELISA

Recommende dilutions:

Request info at info@sobekbio.com

Storage:

PBS with 0.02% sodium azide and 50% glycerol pH 7.4. Store at -20°C. Avoid repeated freeze-thaw cycles.

More info:

Email: info@sobekbio.com

Orders:

Email: orders@sobekbio.com